US Stock MarketDetailed Quotes
PRLD Prelude Therapeutics
- 2.770
- -2.060-42.65%
Close Sep 13 16:00 ET
- 2.800
- +0.030+1.08%
Post 19:53 ET
152.42MMarket Cap-1564P/E (TTM)
5.075High2.690Low2.49MVolume4.900Open4.830Pre Close8.04MTurnover18.11%Turnover RatioLossP/E (Static)55.02MShares6.80052wk High0.84P/B38.05MFloat Cap1.66052wk Low--Dividend TTM13.74MShs Float95.375Historical High--Div YieldTTM49.38%Amplitude1.660Historical Low3.230Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Prelude Therapeutics Stock Forum
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics (NASDAQ: PRLD) announced promising initial clinical data for PRT3789, its first-in-class SMARCA2 degrader, in a Phase 1 trial. The drug showed encouraging anti-tumor activityin patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer. Key findings include:
- 3 confirmed partial re...
On July 10, 2024, Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced a clinical collaboration with Merck. This collaboration aims to evaluate the efficacy of Prelude's investigational drug, PRT3789, in combination with Merck's established anti-PD-1 t...
Prelude Therapeutics Announces Clinical Collaboration With Merck to Evaluate PRT3789 in Combination With Keytruda® (Pembrolizumab) in Patients With Smarca4-Mutated Cancers
Prelude Therapeutics has announced a clinical collaboration with Merck to evaluate the combination of Prelude's PRT3789, a selective SMARCA2 degrader, with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with SMARCA4-mutated cancers. The Phase 2 clinical study aims to explore the potential ...
What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of June 17-21.
Top 5 Buy Calls:
1. Skyworks upgraded to Buy at B. Riley
$Skyworks Solutions (SWKS.US)$
B. Riley upgraded Skyworks (SWKS) to Buy from Neutral with a price target of $130, up from $96, ahead of the July 8 through 11 SEM...
• $Ascendis Pharma A/S (ASND.US)$: BofA Securities Upgrades to Buy from Neutral - PT $161 (from $148)
• $GoodRx (GDRX.US)$: Baird Upgrades to Outperform from Neutral - PT $17
• $W.W. Grainger (GWW.US)$: Atlantic Equities Upgrades to Overweight from Neutral - PT $580 (from $520)
• $Heartland Express (HTLD.US)$: Morgan Stanley Upgrades to Equalweight from Underweight - PT $16
• $The Mosaic (MOS.US)$: Goldman Sachs Upgrades to Buy from Neutral - PT $83
• $Northern Oil & Gas (NOG.US)$: Johnson ...
No comment yet